Latest news with #ChrisBroderick
Yahoo
24-07-2025
- Health
- Yahoo
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs) RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including: Total Addressable Market (TAM)/market opportunity & payer strategy Key findings from ongoing Phase 2 clinical trial of investigational new drug MTX-001 Mechanisms of action Production scale manufacturing plan A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape. 'Standard therapies continue to fail many patients suffering from non-healing VLUs,' said Broderick. 'Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We're honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.' For strategic partnership and collaboration opportunities, please visit For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. CONTACT: Contact Michelle Murray michelle@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Toronto Star
24-07-2025
- Business
- Toronto Star
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including:
Hamilton Spectator
24-07-2025
- Business
- Hamilton Spectator
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including: A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape. 'Standard therapies continue to fail many patients suffering from non-healing VLUs,' said Broderick. 'Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We're honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.' For strategic partnership and collaboration opportunities, please visit . For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ . About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA.
Yahoo
15-07-2025
- Business
- Yahoo
Merakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation Showcase
MTX-001, an investigational new drug, aims to become the first subcutaneous biologic drug therapy for chronic non-healing venous leg ulcers RESEARCH TRIANGLE PARK, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces its amniotic fluid-derived regenerative biologic, MTX-001, an investigational new drug, is a finalist for the Innovation Showcase: Early-Stage Disruptors in Wound Care at the 2025 Advanced Wound Care (AWC) Summit in Boston. Only six companies were chosen by the AWC selection committee to present at the event on July 17, 2025 at 8:30am ET. At the Innovation Showcase, Chris Broderick, Merakris Therapeutics CEO, will present an overview of MTX-001, including promising key findings from the ongoing Phase 2 clinical trial evaluating the therapy in patients with non-healing venous leg ulcers (VLUs) also referred to as venous stasis ulcers (VSUs). 'Non-healing VLUs affect millions of people and a substantial number of patients fail to heal with today's standard therapies,' said Broderick. 'MTX-001 represents a new class of regenerative biologics delivered via subcutaneous injection. This innovation is proving to promote healing in chronic venous wounds and improve patient outcomes.' Also at the 2025 Advanced Wound Care Summit, Sean O'Connell, PhD, Head of Medical Affairs at Merakris Therapeutics, will present 'Injectable Drugs as the Next Big Step for Advanced Wound Care' on July 16th at 3:15pm. His talk will review the MTX-001 clinical program, interim Phase 2 results, and outline upcoming plans for a Phase 3 clinical trial. He will also highlight the unmet needs in the chronic wound market and the emerging role of injectable biologics in outpatient care. For strategic partnership and collaboration opportunities, please visit For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. CONTACT: PR Contact: Garth Miller Nova Marketing Solutions 919-923-3505Sign in to access your portfolio
The Sun
04-06-2025
- Entertainment
- The Sun
Legendary metal band shock fans as member exits after seven years
MUSIC fans have been left reeling following one member's shock departure from a legendary metal band. Supporters of the group are in shock after the drummer downed his sticks and walked away just days before their massive European tour. 5 5 In Flames announced the news on the band's social media accounts, telling fans they had "parted ways" with Tanner Wayne. In a statement released on Instagram, In Flames said: "It is with profound gratitude and and appreciation that we announce our creative decision to part ways with Tanner Wayne. "His dedication and musicianship over the past several years has left, and will continue to leave, a lasting mark on this band. "We wish him nothing but the best." The Swedish band, which was formed 35 years ago, concluded: "We appreciate your support and understanding at this time and hope to see you all on tour this summer." Tanner, 37, joined In Flames in July 2018 when he replaced drummer Joe Rickard. The US musician had begun his drumming career in the hardcore punk band Underminded in 2006, but only featured on one album. He went on to drum for Chiodos and Suicide Silence before his seven-year stint with In Flames. Tanner's shock exit from the band came just days before they kicked off their European tour in Estonia. For the next month, the group - consisting of Björn Gelotte, Anders Fridén, Chris Broderick and Liam Wilson - will be performing across central Europe, eventually wrapping up Sweden. But despite Tanner walking away, the shows will go on. In Flames has already recruited a new drummer who accompanied them on their opening night in Tallin, Estonia, on Monday. Jon Rice has stepped in for the band's high profile tour and appears to have slotted right in. Alongside a photo of himself playing on stage, Jon wrote on Instagram: "Show #1 done. Thank you for the warm welcome, Tallinn. "And thank you to @inflames for having me and trusting me with your tunes." In Flames was originally formed by guitarist Jesper Strömblad in Gothenburg out of the Swedish death metal scene in 1990. The lineup has changed multiple times over the past three decades, however vocalist Anders Fridén and guitarist Björn Gelotte have remained consistent since 1995. 5 5
